Wedbush Raises Earnings Estimates for Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) – Wedbush increased their FY2027 earnings per share estimates for Ascendis Pharma A/S in a research report issued on Thursday, November 13th. Wedbush analyst Y. Zhong now expects that the biotechnology company will post earnings per share of $7.22 for the year, up from their prior estimate of $7.05. Wedbush has a “Outperform” rating and a $220.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($4.34) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s FY2028 earnings at $13.58 EPS and FY2029 earnings at $18.50 EPS.

Other equities analysts also recently issued reports about the company. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Raymond James Financial started coverage on Ascendis Pharma A/S in a research report on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 target price on the stock. Wells Fargo & Company reiterated an “overweight” rating and set a $295.00 price target (up previously from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Bank of America increased their price target on Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Finally, Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an “overweight” rating in a research note on Monday, October 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.71.

Ascendis Pharma A/S Trading Down 1.0%

NASDAQ ASND opened at $204.40 on Friday. The company has a 50-day moving average price of $201.86 and a two-hundred day moving average price of $184.58. Ascendis Pharma A/S has a 52 week low of $118.03 and a 52 week high of $219.30. The stock has a market cap of $12.61 billion, a price-to-earnings ratio of -39.61 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $290.24 million for the quarter, compared to analysts’ expectations of $246.91 million.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently modified their holdings of ASND. Allianz Asset Management GmbH increased its holdings in shares of Ascendis Pharma A/S by 144.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock valued at $1,605,000 after purchasing an additional 5,500 shares during the period. Vident Advisory LLC acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $273,000. Goldman Sachs Group Inc. grew its position in Ascendis Pharma A/S by 10.4% during the first quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock valued at $91,269,000 after purchasing an additional 55,164 shares in the last quarter. Hantz Financial Services Inc. increased its stake in Ascendis Pharma A/S by 291.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 262 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Ascendis Pharma A/S in the 2nd quarter worth approximately $682,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.